MMR vaccination and disease elimination: the Finnish experience
- PMID: 20822347
- DOI: 10.1586/erv.10.99
MMR vaccination and disease elimination: the Finnish experience
Abstract
Measles, mumps and rubella (MMR) vaccinations have been included in Finland's national vaccination program as a two-dose schedule since 1982. Owing to the high (>95%) coverage of vaccinations, indigenous MMR diseases were eliminated from Finland by the mid-1990s. In 1982, the incidence of measles, mumps and rubella was 105, 43 and 64 per 100,000 population, respectively, but declined to 0.1 per 100,000 population for all MMR diseases in 1995. Since then, the few cases of measles, mumps and rubella imported annually have not caused any outbreaks. Several research projects that started along with the vaccination campaign have provided important support throughout the program. The vaccine was proven to be safe, immunogenic and effective. Antibody follow-up has revealed that MMR vaccine-induced antibodies wane over time, and concerns have arisen about the continuation of this good situation. High vaccination coverage, enhanced surveillance and preparedness to administer additional doses when needed are key factors for future success. Here we present an overview of MMR vaccinations and the Finnish experience of the MMR disease elimination process, and we describe surveillance activities in the era following elimination in Finland.
Similar articles
-
The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.N Engl J Med. 1994 Nov 24;331(21):1397-402. doi: 10.1056/NEJM199411243312101. N Engl J Med. 1994. PMID: 7969278
-
An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.J Infect Dis. 2004 May 1;189 Suppl 1:S131-45. doi: 10.1086/378987. J Infect Dis. 2004. PMID: 15106102
-
Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.J Infect Dis. 2008 Apr 1;197(7):950-6. doi: 10.1086/528993. J Infect Dis. 2008. PMID: 18419470
-
Measles, mumps, rubella prevention: how can we do better?Expert Rev Vaccines. 2021 Jul;20(7):811-826. doi: 10.1080/14760584.2021.1927722. Epub 2021 Jun 7. Expert Rev Vaccines. 2021. PMID: 34096442 Review.
-
The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.Dev Biol Stand. 1986;65:45-52. Dev Biol Stand. 1986. PMID: 3104117 Review.
Cited by
-
Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.Eur J Pediatr. 2015 Jul;174(7):925-32. doi: 10.1007/s00431-014-2481-5. Epub 2015 Jan 13. Eur J Pediatr. 2015. PMID: 25579232
-
Synthesis of Evidence to Characterize National Measles and Rubella Exposure and Immunization Histories.Risk Anal. 2016 Jul;36(7):1427-58. doi: 10.1111/risa.12454. Epub 2015 Aug 6. Risk Anal. 2016. PMID: 26249328 Free PMC article.
-
Cost of Public Health Response and Outbreak Control With a Third Dose of Measles-Mumps-Rubella Vaccine During a University Mumps Outbreak-Iowa, 2015-2016.Open Forum Infect Dis. 2018 Oct 4;5(10):ofy199. doi: 10.1093/ofid/ofy199. eCollection 2018 Oct. Open Forum Infect Dis. 2018. PMID: 30302350 Free PMC article.
-
Vaccines for measles, mumps, rubella, and varicella in children.Cochrane Database Syst Rev. 2020 Apr 20;4(4):CD004407. doi: 10.1002/14651858.CD004407.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407. doi: 10.1002/14651858.CD004407.pub5. PMID: 32309885 Free PMC article. Updated.
-
Outbreak of mumps in a student population with high vaccination coverage in China: time for two-dose vaccination.Hum Vaccin Immunother. 2019;15(9):2106-2111. doi: 10.1080/21645515.2019.1581526. Epub 2019 Mar 15. Hum Vaccin Immunother. 2019. PMID: 30779678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical